Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399045 | 0.93 | KDM4E (0.86) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL30906932 | 0.93 | KDM4E (0.86) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL30906933 | 0.93 | KDM4E (0.86) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL30417603 | 0.86 | KDM4E (0.76) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL12486470 | 0.82 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7121601 | 0.82 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL27977216 | 0.81 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL262202 | 0.80 | KDM4E (0.67) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7127052 | 0.80 | KDM4E (0.67) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL28285317 | 0.80 | MEN1 (0.82) | KDM4EMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| WO-2010055135-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| US-7323596-B2 | Antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH( .dbd. O) or of formula C( .dbd. O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of | DE NOVO PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20040102491-A1 | Antimicrobial agents | DE NOVO PHARMACEUTICALS LTD. (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5362734-A | Certain benzo-quinolizine compounds and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| US-5225419-A | Antagonist 5-hydroxytryptamine for treatment of nausea or vomiting | JOHN WYETH & BROTHER, LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | GHRHR, GHITM, GHSR | KDM4E 3518/4885MEN1 1365/4885KMT2A 3404/4885 |
| US-20040102491-A1 | Antimicrobial agents | CBR1, CYC1, MRM1 | KDM4E 2673/4885MEN1 2961/4885KMT2A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.